-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2721 COVID-19 Associated Coagulopathy: Thrombosis, Hemorrhage and Mortality Rates with an Escalated-Thromboprophylaxis Strategy

Program: Oral and Poster Abstracts
Session: 332. Anticoagulation and Antithrombotic Therapy: Poster III
Hematology Disease Topics & Pathways:
anticoagulant drugs, SARS-CoV-2/COVID-19, Coronaviruses, Non-Biological, Diseases, Bleeding and Clotting, Therapies, Thrombosis, Thromboembolism, Clinically relevant, Quality Improvement , Thrombotic Disorders, VTE
Monday, December 7, 2020, 7:00 AM-3:30 PM

Molly Daughety, MD1*, Thomas L. Ortel, MD, PhD2, Erin Frost, MD1*, Andrew Morgan, MD/PhD1*, Chester Kao, MD1*, Joyce Hwang, MD1*, Bhavik Patel, MD1* and Ian J Welsby, MBBS3*

1Duke University Medical Center, Durham, NC
2Department of Medicine, Duke University Medical Center, Durham, NC
3Division of Cardiothoracic Anesthesia, Department of Anesthesiology, Duke University Medical Center, Durham, NC

Introduction: Early studies identified a prothrombotic state associated with novel coronavirus disease 2019 (COVID-19) as well as a survival benefit observed with heparin use in severely ill COVID-19 patients. There is a need to clarify the incidence of thromboembolic events (TEs), as well as major hemorrhage in COVID-19 patients in the context of an escalated-dose thromboprophylaxis strategy.

Methods: We conducted a single center, retrospective study of 192 consecutive patients with COVID-19 admitted to the hospital between March 26th and May 8th 2020. Our study aimed to investigate the rates of thromboembolic events (TEs), hemorrhage and mortality of in the context of an escalated-dose thromboprophylaxis strategy implemented early in our experience with hospitalized patients with COVID-19.

Results: The incidence of radiographically-confirmed venous thromboembolism (VTE) was 7.3% (n=14), and the rate of combined TEs was 12% (n=23). The rate of major hemorrhage was 6.3% (n=12), including one fatal CNS bleed. The overall mortality rate was 27.6% (n=53).

Conclusion: The rate of VTE and overall TE was much lower than was reported in early studies, and the majority of VTEs occurred in ambulatory patients. Our data suggest that an escalated-dose thromboprophylaxis strategy may help reduce the incidence of inpatient VTEs, and that ambulatory COVID-19 patients may benefit from primary thromboprophylaxis. However, the risk of bleeding was not negligible, and must therefore be assessed on an individual and continual basis when using a more aggressive thromboprophylaxis strategy.

Disclosures: No relevant conflicts of interest to declare.

<< Previous Abstract | Next Abstract
*signifies non-member of ASH